about CAR T
Our mission is to develop CAR T therapies that produce a better and more durable response than previous CAR T generations, improving treatment outcomes and saving the lives of patients with refractory cancers.
Join us at GammaDelta T Therapies Summit where our CSO, Dr John Maher, will be presenting our work on gd T cell immunotherapy of solid tumours
July 27-29, 2021 | 100% Online
9.30am – 5.30pm EST
6.30am – 2.30pm PST
CAR T cells are genetically altered immune cells engineered to hunt down and destroy cancer cells.
Parallel CAR T Cell Platform
Leucid has developed a proprietary engine that develops CAR T molecules designed to be in more natural biological cell configurations. These are called parallel CAR T or pCAR T therapies. The pCAR T model has consistently outperformed previous generations of CAR T therapies in pre-clinical studies by enhancing T cell potency and generating a persistent long-term response.
Leucid’s first clinical asset is a pan-ErbB targeted autologous CAR T cell product for patients with otherwise untreatable head and neck cancer. It is currently in Phase I and 16 patients have been treated at doses of up to 1 billion CAR T cells of whom 10 have achieved disease stabilisation.
Novel Manufacturing Platforms
Leucid has developed an improved, more rapid and scalable manufacturing route that relies on a simple blood draw.